Oral immunomodulation therapy in rheumatoid arthritis

Joint Bone Spine

Volumn 67, Issue 5, 2000, Pages 384-392

  Meyer, O ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Collagen II; Juvenile idiopathic arthritis; Nasal tolerance; Oral tolerance; Rheumatoid arthritis; TGF ; Th3; Tolerance

Indexed keywords

COLLAGEN TYPE 2; IMMUNOMODULATING AGENT; INSULIN; MYELIN BASIC PROTEIN; OVALBUMIN; PEPTIDE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA;

CLINICAL TRIAL; EFFECTOR CELL; HELPER CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOTHERAPY; JUVENILE RHEUMATOID ARTHRITIS; LYMPHATIC SYSTEM; LYMPHOCYTE DEPLETION; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE SUBPOPULATION; TH2 CELL;

ADMINISTRATION, ORAL; ANIMALS; ARTHRITIS, RHEUMATOID; CATTLE; DISEASE MODELS, ANIMAL; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; INTESTINAL MUCOSA; LYMPHOID TISSUE;

EID: 0033710056     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. History of oral tolerance and mucosal immunity. Oral tolerance, mechanisms and applications
2. Oral tolerance: Immune mechanisms and treatment of autoimmune diseases
3. Dose-dependent activation and deletion of antigen-specific T cells following oral tolerance
4. Mucosal tolerance: A two-edged sword to prevent and treat autoimmune disease
5. Conversion by Peyer's patch lymphocytes of human enterocytes into M cells that transport bacteria
6. α4β7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1
7. Differential expression in rheumatoid synovium and synovial fluid of α4β7 integrin
8. Peripheral deletion of antigen-reactive T cells in oral tolerance
9. Oral tolerance in humans. T cell but not B cell tolerance after antigen feeding
10. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and factor β, interleukin 4 and prostaglandin E expression in the brain
11. Oral tolerance: Immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens
12. Immune responses to dietary antigens: Oral tolerance
13. The intestinal epithelial cell: Processing and presentation of antigen to the mucosal immune system
14. Visualising the T-cell response elicited by oral administration of soluble protein antigen
15. Expanding dendritic cells in vivo enhances the induction of oral tolerance
16. CD8 T-cells are not essential for the induction of 'low-dose' oral tolerance
17. Monocyte chemotactic protein 1 regulates oral tolerance induction by inhibition of T helper cell 1-related cytokines
18. γδ T lymphocytes regulate the induction and maintenance of oral tolerance
19. Intraepithelial lymphocytes of the intestinal mucosa: Curiouser and curiouser
20. Gammadelta T cells regulate mucosally induced tolerance in a dose-dependent fashion
21. Immunoregulatory functions for murine intraepithelial lymphocytes γ/δ T cell receptor-positive (TCR+) T cells abrogate oral tolerance, while α/β TCR+ cells provide B cell help
22. Immunoprophylaxis of atopy. Light at the end of the tunnel?
23. Orally induced, peptidespecific γ/δ TCR+ cells suppress experimental autoimmune uveitis
24. Orally induced peripheral nonresponsiveness is maintained in the absence of functional Th1 or Th2 cells
25. Oral tolerization as a treatment of rheumatoid arthritis
26. Oral collagen in the treatment of rheumatoid arthritis
27. Mucosal tolerance and rheumatoid arthritis
28. Murine model of oral tolerance. Induction of Fas-mediated apoptosis by blockade of interleukin-12
29. Oral tolerance in myelin basic protein T-cell receptor transgenic mice: Suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells
30. CTLA-4 is required for the induction of high dose oral tolerance
31. Combination therapy with oral myelin basic protein and oral methotrexate enhances suppression of experimental autoimmune encephalomyelitis
32. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen
33. Modulation by cytokines of induction of oral tolerance to type II collagen
34. Gastric administration of type II collagen delays the onset and severity of collagen-induced arthritis in rats
35. Oral administration of an immunodominant human collagen peptide modulates collagen-induced arthritis
36. Suppression of murine collagen-induced arthritis by nasal administration of collagen
37. Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope
38. Suppression of collagen induced arthritis by oral administration of type II collagen: Changes in immune and arthritic responses mediated by active peripheral suppression
39. Suppression of adjuvant arthritis in Lewis rats by oral administration of type II collagen
40. Suppression of antigen-induced arthritis in Lewis rats by oral administration of type II collagen
41. Prevention of pristane-induced arthritis by the oral administration of type II collagen
42. Peptide-induced nasal tolerance for a mycobacterial heat shock protein 60 T cell epitope in rats suppresses both adjuvant arthritis and nonmicrobially induced experimental arthritis
43. Gastric administration of recombinant 65 kDa heat shock protein delays the severity of type II collagen induced arthritis in mice
44. Oral delivery of group A streptococcal cell walls augments circulating TGF-β and suppresses streptococcal cell wall arthritis
45. Intranasally induced immunological tolerance is determined by characteristics of the draining lymph nodes: Studies with OVA and human cartilage gp-39
46. Effects of oral administration of type II collagen on rheumatoid arthritis
47. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial
48. Oral type II collagen treatment in early rheumatoid arthritis. A double-blind, placebo-controlled, randomized trial
49. Die entwicklung der funktionskapazitst und der schmerzintensitat von 81 cl-patienten unterliner behandlung mit azulfidine RA oder aurothioglucose
50. A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis
51. Type II collagen serology: A guide to clinical responsiveness to oral tolerance?
52. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23)
53. Induction of tolerance with intranasal administration of human cartilage gp 39 in DBA/I mice